PDCD1 and esophageal squamous cell carcinoma: Among them, the ESCORT‐1st trial conducted by our group found that the administration of a PD‐1 mAb (camrelizumab) in combination with chemotherapy significantly improved progression‐free survival and overall survival of advanced or metastatic ESCC patients.3